The use of MEK inhibitors (MEKi) in combination with BRAFi was to prevent the paradoxical and reactivation of the MAPK pathway that leads to resistance and cSCC development [58,93,100,101]. This evidence concerns the gene MAP2K7 and skin squamous cell carcinoma.